Will Insurance Cover Retatrutide?
Last updated: January 2026
Quick Answer
Coverage will likely follow the tirzepatide pattern — covered with T2D diagnosis more readily than for obesity alone. Expect the same prior authorization challenges that affect current GLP-1s. Until approved, it's not prescribable or insurable.
Will Insurance Cover Retatrutide
Coverage will likely follow the tirzepatide pattern — covered with T2D diagnosis more readily than for obesity alone. Expect the same prior authorization challenges that affect current GLP-1s. Until approved, it's not prescribable or insurable.
Insurance coverage for GLP-1 medications has expanded significantly in recent years, driven by growing clinical evidence and the FDA's cardiovascular risk reduction approval for semaglutide. However, coverage varies widely between insurance plans, employers, and states.
How to Check Your Coverage
The most reliable way to check GLP-1 coverage is to call the number on the back of your insurance card and ask specifically about weight management medications. Request information about your plan's formulary, prior authorization requirements, and any step therapy protocols.
What If You Are Not Covered?
- File an appeal with documentation of medical necessity
- Ask your provider about peer-to-peer review with the insurance medical director
- Consider compounded GLP-1 through a telehealth provider ($149-449/month)
- Use HSA/FSA pre-tax funds regardless of insurance coverage
- Check manufacturer patient assistance programs for brand-name options
Even without insurance coverage, compounded GLP-1 medications through telehealth providers are often more affordable than the copay on brand-name drugs with insurance.
Related Questions
How Much Will Retatrutide Cost?
Retatrutide isn't yet approved. Based on tirzepatide pricing trends, brand-name retatrutide may cost $900-1,300/month without insurance. Compounded versions (if allowed after approval) could be $249-399/month, similar to tirzepatide today.
When Will Retatrutide Be FDA Approved?
Eli Lilly launched the Phase 3 TRIUMPH program in 2024. FDA submission is expected in 2026, with potential approval in 2026-2027. Phase 3 results from the TRIUMPH-3 trial are expected in late 2025.